Alkermes expects 18% revenue growth in 3Q26 but sees EPS drop due to high costs, driven by LUMRYZ and pipeline progress.

Alkermes is projected to report 18% year-over-year revenue growth in 3Q26, reaching $465.1 million, driven by strong commercial momentum of LUMRYZ and a promising neuroscience drug pipeline. However, adjusted earnings per share (EPS) are expected to decline by 64.3% sequentially due to elevated research and development (R&D) and selling, general, and administrative (SG&A) expenses. Near-term performance will focus on patient growth for LUMRYZ and prescription trends for LYBALVI, while long-term investment appeal is supported by clinical progress of Alixorexton. Despite revenue growth, profitability pressures remain, making sustained earnings recovery critical for a more positive outlook on Alkermes.

Alkermes shares trade at USD 45.37 on Pluang as of Oct 30, 2026 01:51 WIB, showing a modest 0.27% gain for the day. The stock's market cap stands at $7.59 billion, reflecting investor interest despite recent earnings challenges. Trading volume reached 1,439,609 shares, indicating active market participation around the earnings report period.